Proceedings of the fourth international conference on central hypoventilation
Authors:
- the European Central Hypoventilation Syndrome ConsortiumTCthe European Central Hypoventilation Syndrome Consortium
- Ha TrangHTHa Trang
- Jean-François BrunetJBJean-François Brunet
- Hermann RohrerHRHermann Rohrer
- Jorge GallegoJGJorge Gallego
- Jeanne AmielJAJeanne Amiel
- Tiziana BachettiTBTiziana Bachetti
- Kenneth H FischbeckKFKenneth H Fischbeck
- Thomas SimilowskiTSThomas Similowski
- Christian StrausCSChristian Straus
- Isabella CeccheriniIsabella Ceccherini
- Debra E Weese-MayerDWDebra E Weese-Mayer
Open Access
- 5 December 2014
- journal article
- review article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 194
Abstract
Central hypoventilation syndromes (CHS) are rare diseases of central autonomic respiratory control associated with autonomous nervous dysfunction. Severe central hypoventilation is the hallmark and the most life-threatening feature. CHS is a group of not-fully defined disorders. Congenital CHS (CCHS) (ORPHA661) is clinically and genetically well-characterized, with the disease-causing gene identified in 2003. CCHS presents at birth in most cases, and associated with Hirschsprung’s disease (ORPHA99803) and neural crest tumours in 20% and 5% of cases, respectively. The incidence of CCHS is estimated to be 1 of 200,000 live births in France, yet remains unknown for the rest of the world. In contrast, late-onset CHS includes a group of not yet fully delineated diseases. Overlap with CCHS is likely, as a subset of patients harbours PHOX2B mutations. Another subset of patients present with associated hypothalamic dysfunction. The number of these patients is unknown (less than 60 cases reported worldwide). Treatment of CHS is palliative using advanced techniques of ventilation support during lifetime. Research is ongoing to better understand physiopathological mechanisms and identify potential treatment pathways. The Fourth International Conference on Central Hypoventilation was organised in Warsaw, Poland, April 13–15, 2012, under the patronage of the European Agency for Health and Consumers and Public Health European Agency of European Community. The conference provided a state-of-the-art update of knowledge on all the genetic, molecular, cellular, and clinical aspects of these rare diseases.Keywords
This publication has 124 references indexed in Scilit:
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trialThe Lancet Neurology, 2011
- The Relationship Between Home Nursing Coverage, Sleep, and Daytime Functioning in Parents of Ventilator-Assisted ChildrenJournal of Pediatric Nursing, 2010
- A bench study of intensive-care-unit ventilators: new versus old and turbine-based versus compressed gas-based ventilatorsIntensive Care Medicine, 2009
- Central Alveolar Hypoventilation SyndromesSleep Medicine Clinics, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- Effect of sleep stage on breathing in children with central hypoventilationJournal of Applied Physiology, 2008
- A human mutation in Phox2b causes lack of CO 2 chemosensitivity, fatal central apnea, and specific loss of parafacial neuronsProceedings of the National Academy of Sciences, 2008
- Specification of catecholaminergic and serotonergic neuronsNature Reviews Neuroscience, 2002